Aleš Chodacki

4.5k total citations
10 papers, 463 citations indexed

About

Aleš Chodacki is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Aleš Chodacki has authored 10 papers receiving a total of 463 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 10 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Oncology. Recurrent topics in Aleš Chodacki's work include Radiopharmaceutical Chemistry and Applications (10 papers), Prostate Cancer Treatment and Research (10 papers) and Bone health and treatments (4 papers). Aleš Chodacki is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (10 papers), Prostate Cancer Treatment and Research (10 papers) and Bone health and treatments (4 papers). Aleš Chodacki collaborates with scholars based in United Kingdom, Sweden and United States. Aleš Chodacki's co-authors include Joe M. O’Sullivan, Peter Hoskin, Chris Parker, Oliver Sartor, Sophie D. Fosså, Daniel Heinrich, J. Garcia‐Vargas, Trond Haider, Josep R. Germà and S. Pascoe and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Urology and Annals of Oncology.

In The Last Decade

Aleš Chodacki

9 papers receiving 455 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aleš Chodacki United Kingdom	7	405	291	209	73	60	10	463
Christoph A. von Klot Germany	13	477 1.2×	288 1.0×	72 0.3×	110 1.5×	19 0.3×	20	653
Marie Hjälm-Eriksson Sweden	8	367 0.9×	83 0.3×	113 0.5×	111 1.5×	36 0.6×	17	455
Jérémy Lévy Switzerland	7	185 0.5×	178 0.6×	124 0.6×	52 0.7×	22 0.4×	11	289
Robert Reid United States	7	278 0.7×	223 0.8×	252 1.2×	74 1.0×	7 0.1×	12	487
Nicola Jane Lawrence Australia	7	249 0.6×	113 0.4×	167 0.8×	88 1.2×	14 0.2×	24	358
Frank Verholen Switzerland	9	309 0.8×	187 0.6×	96 0.5×	92 1.3×	52 0.9×	43	372
Álvaro Juárez Spain	5	307 0.8×	124 0.4×	51 0.2×	97 1.3×	38 0.6×	11	328
Cameron S. Liu United States	3	229 0.6×	114 0.4×	88 0.4×	68 0.9×	110 1.8×	6	334
Katherine Sunderland Canada	10	694 1.7×	190 0.7×	230 1.1×	331 4.5×	39 0.7×	23	761
Bernhard Grubmüller Austria	12	615 1.5×	434 1.5×	120 0.6×	81 1.1×	5 0.1×	33	681

Countries citing papers authored by Aleš Chodacki

Since Specialization

Citations

This map shows the geographic impact of Aleš Chodacki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aleš Chodacki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aleš Chodacki more than expected).

Fields of papers citing papers by Aleš Chodacki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aleš Chodacki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aleš Chodacki. The network helps show where Aleš Chodacki may publish in the future.

Co-authorship network of co-authors of Aleš Chodacki

This figure shows the co-authorship network connecting the top 25 collaborators of Aleš Chodacki. A scholar is included among the top collaborators of Aleš Chodacki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aleš Chodacki. Aleš Chodacki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Logue, John, Saskia Wedel, Aleš Chodacki, et al.. (2014). Reasons for Patients (Pts) Discontinuing Study Treatment (Tx) in the Phase 3 Alsympca Trial of Radium-223 Dichloride (Ra-223) in Castration-Resistant Prostate Cancer (Crpc) with Bone Metastases (Mets). Annals of Oncology. 25. iv264–iv264. 6 indexed citations

2.

Heinrich, Daniel, Svein Inge Helle, Aleš Chodacki, et al.. (2013). 101 Updated analysis of radium-223 dichloride (Ra-223) impact on pain, skeletal-related events (SRE), and survival from the phase 3 randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) and bone metastases. European Urology Supplements. 12(1). e101–e102.

3.

Parker, Christopher, S. Pascoe, Aleš Chodacki, et al.. (2012). A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer. European Urology. 63(2). 189–197. 133 indexed citations

4.

Sartor, Oliver, Daniel Heinrich, Joe M. O’Sullivan, et al.. (2012). Radium-223 chloride (Ra-223) impact on skeletal-related events (SREs) and ECOG performance status (PS) in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Interim results of a phase III trial (ALSYMPCA).. Journal of Clinical Oncology. 30(15_suppl). 4551–4551. 12 indexed citations

5.

Parker, Chris, Sten Nilsson, Daniel Heinrich, et al.. (2012). Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).. Journal of Clinical Oncology. 30(15_suppl). LBA4512–LBA4512. 61 indexed citations

6.

Sartor, Oliver, Daniel Heinrich, Svein Inge Helle, et al.. (2012). 684 RADIUM-223 CHLORIDE (ALPHARADIN) IMPACT ON OVERALL SURVIVAL AND SKELETAL-RELATED EVENTS IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER WITH BONE METASTASES A PHASE III RANDOMIZED TRIAL (ALSYMPCA). The Journal of Urology. 187(4S). 2 indexed citations

7.

Sartor, Oliver, Daniel Heinrich, Svein Inge Helle, et al.. (2012). Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA).. Journal of Clinical Oncology. 30(5_suppl). 9–9. 32 indexed citations

8.

Parker, Chris, Sten Nilsson, Daniel Heinrich, et al.. (2012). Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).. Journal of Clinical Oncology. 30(18_suppl). LBA4512–LBA4512. 26 indexed citations

9.

Parker, Chris, Daniel Heinrich, Joe M. O’Sullivan, et al.. (2012). Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases.. Journal of Clinical Oncology. 30(5_suppl). 8–8. 83 indexed citations

10.

Parker, Chris, Daniel Heinrich, Joe M. O’Sullivan, et al.. (2011). Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA). European Journal of Cancer. 47. 3–3. 108 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact